Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Oncol
Glavni autori: Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Format: Artigo
Jezik:Inglês
Izdano: Hindawi 2020
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://ncbi.nlm.nih.gov/pubmed/32411240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7131802
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items